Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina
Shanghai CirCode Biomed Co. Ltd. announced that its self‑developed circular RNA (circRNA) therapeutic HM2002 has received...
Shanghai CirCode Biomed Co. Ltd. announced that its self‑developed circular RNA (circRNA) therapeutic HM2002 has received...
Shanghai CirCode Biomed Co. Ltd. today announced that its proprietary circular‑RNA (circRNA) therapeutic HM2003 Injection...
Yanyin Tech and Shanghai CirCode Biomed Co. Ltd. have announced a three-year strategic cooperation agreement...
China-based Shanghai CirCode Biomed Co. Ltd., a specialist in circular RNA therapies, announced that its...
Shanghai Circode Bio has entered into a feasibility study cooperation agreement with US pharmaceutical giant...
Shanghai Circode Bio has entered into a partnership with US pharmaceutical giant Pfizer (NYSE: PFE)...